Applying value-based insurance design to high-cost health services

Health Affairs

Volumn 29, Issue 11, 2010, Pages 2009-2016

  Robinson, James C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; COST CONTROL; ECONOMICS; HEALTH INSURANCE; HEALTH SERVICE; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; UNITED STATES;

COST CONTROL; COST SHARING; HEALTH SERVICES; INSURANCE, HEALTH; MODELS, ORGANIZATIONAL; UNITED STATES;

EID: 79952276658     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0469     Document Type: Article

References (33)

1. Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. Low-value services in value-based insurance design. Am J Manag Care. 2010;16:280-6.
2. Newhouse JP, Insurance Experiment Group. Free for all? Lessons fromthe RAND Health Insurance Experiment. Cambridge (MA): Harvard University Press; 1993.
3. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-9.
4. Trivedi AN, Swaminathan S, Mor V. Insurance parity and the use of outpatient mental health care following a psychiatric hospitalization. JAMA. 2008;300:2879-85.
5. Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. N Engl J Med. 2008;358:375-83.
6. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006; 354:2349-59.
7. Trivedi AN, Maloo H, Mor V. Increased ambulatory care copayments and hospitalizations in the elderly. N Engl J Med. 2010;362:320-8.
8. Chernew ME, Juster IA, Shah I, Wegh A, Rosenburg S, Rosen AB, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-6.
9. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2): w195-203.
10. Fendrick AM. Value-based insurance design landscape digest. Washington (DC): National Pharmaceutical Council; 2009.
11. Robinson JC. Consumer-directed health insurance: the next generation. Health Aff (Millwood). 2005;24(6):w5-583-90. DOI:10.1377/hlthaff.W5.583.
12. Stafford RS. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008;358: 1427-30.
13. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006; 185:544-8.
14. National Comprehensive Cancer Network. Managed care and medical oncology: 'cancer is now on the table' [Internet]. Fort Washington (PA): The Network; 2009 [cited 2010 Sep 29]. Available from: http://www.nccn.org/network/business_insights/oncology_trends/manged_care.asp
15. Phillips KA, Vennstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004; 10:425-32.
16. Lee SC, Bernhardt BA, Helzsouer KJ. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. Cancer. 2002;94:1876-85.
17. Garber AM, McClellan MB. Satisfaction guaranteed: payment by results for biologic agents. N Engl J Med. 2007;357:1575-7.
18. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's -coverage with evidence development. Health Aff (Millwood). 2006;25(5):1218-30.
19. Weinstein JN, Clay K, Morgan TS. Informed patient choice: patientcentered valuing of surgical risks and benefits. Health Aff (Millwood). 2007;26(3):726-30.
20. Kaiser Family Foundation, Health Research and Educational Trust. Employer health benefits: 2009 annual survey [Internet]. Menlo Park (CA): KFF; 2009 Sep [cited 2009 Dec 1]. Available from: http://www.kff.org/insurance/7936/index.cfm
21. US Government Accountability Office. Medicare Part D: spending, beneficiary cost sharing, and costcontainment efforts for high-cost drugs eligible for a specialty tier [Internet]. Washington (DC): GAO; 2010 Jan [cited 2010 Sep 29]. Available from: http://www.gao.gov/products/GAO-10-242
22. Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. N Engl J Med. 2008;359:333-5.
23. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-31.
24. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin. 2007;23: 1749-59.
25. Robinson JC. Value-based purchasing for medical devices. Health Aff (Millwood). 2008;27(6):1523-31.
26. Montgomery K, Schneller ES. Hospitals' strategies for orchestrating selection of physician preference items. Milbank Q. 2007;85:307-35.
27. Wilson NA, Schneller ES, Montgomery K, Bozic KJ. Hip and knee implants: current trends and policy considerations. Health Aff (Millwood). 2008;27(6):1587-98.
28. Baker LC, Atlas SW, Afendulis CC. Expanded use of imaging technology and the challenge of measuring value. Health Aff (Millwood). 2008; 27(6):1467-78.
29. Levin DC, Bree RL, Rao VM, Johnson J. A prior authorization program of a radiology benefits management company and how it has affected utilization of advanced diagnostic imaging. J Am Coll Radiol. 2010; 7:33-8.
30. Redberg RF, Walsh J. Pay now, benefits may follow: the case of cardiac computed tomographic angiography. N Engl J Med. 2008;359:2309-11.
31. Pearson SD, Knudsen AB, Scherer RW, Weissberg J, Gazelle GS. Assessing the comparative effectiveness of a diagnostic technology: CT colonoscopy. Health Aff (Millwood). 2008;27(6):1503-14.
32. Hackbarth G, Reischauer R, Mutti A. Collective accountability for medical care: toward bundled Medicare payments. N Engl J Med. 2008;359:3-6.
33. Robinson JC. Hospital tiers in health insurance: balancing consumer choice with financial incentives. Health Aff (Millwood). 2003;22(3): w3-35-46. DOI:10.1377/hlthaff .w3.135.